welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
Safety, Tolerability, and Pharmacokinetics of SMT C1100, a 2-Arylbenzoxazole Utrophin Modulator, following Single- and Multiple-Dose Administration to Pediatric Patients with Duchenne Muscular Dystrophy
source: PloS One
year: 2016
authors: Ricotti V, Spinty S, Roper H, Hughes I, Tejura B, Robinson N, Layton G, Davies K, Muntoni F, Tinsley J
summary/abstract:Purpose:
SMT C1100 is a utrophin modulator being evaluated as a treatment for Duchenne muscular dystrophy (DMD). This study, the first in pediatric DMD patients, reports the safety, tolerability and PK parameters of single and multiple doses of SMT C1100, as well as analyze potential biomarkers of muscle damage.
Methods:
This multicenter, Phase 1 study enrolled 12 patients, divided equally into three groups (A-C). Group A were given 50 mg/kg on Days 1 and 11, and 50 mg/kg bid on Days 2 to 10. Group B and C received 100 mg/kg on Days 1 and 11; Group B and Group C were given 100 mg/kg bid and 100 mg/kg tid, respectively, on Days 2 to 10. A safety review was performed on all patients following the single dose and there was at least 2 weeks between each dose escalation, for safety and PK review. Adverse events (AEs) were monitored throughout the study.
Results:
Most patients experienced mild AEs and there were no serious AEs. Two patients required analgesia for pain (headache, ear pain and toothache). One patient experienced moderate psychiatric AEs (abnormal behaviour and mood swings). Plasma concentrations of SMT C1100 at Days 1 and 11 indicated a high degree of patient variability regardless of dose. Unexpectedly the SMT C1100 levels were significantly lower than similar doses administered to healthy volunteers in an earlier clinical study. In general, individual baseline changes of creatine phosphokinase, alanine aminotransferase, aspartate aminotransferase levels fell with SMT C1100 dosing.
Conclusions:
SMT C1100 was well tolerated in pediatric DMD patients.
organization: UCL Institute of Child Health, UK; Alder Hey Children's NHS Foundation Trust, UK; Birmingham Heartlands Hospital, UK; Royal Manchester Children's Hospital, UK; Summit Therapeutics, UK; S.H.B. Enterprises Limited, UK; ParamStat Limited, UK; University of Oxford, UKDOI: 10.1371/journal.pone.0152840
read more full text source
rareRelated
-
A Phase 1b Study of SMT C1100 in Subjects With Duchenne Muscular Dystrophy (DMD)The purpose of this study is to determin...
-
Future Clinical And Biomarker Development For SMT C1100, The First Utrophin Modulator To Enter Clinical Trials For D...Objective: To progress SMT C1100, Summi...
-
Proof of Concept Study to Assess Activity and Safety of SMT C1100 (Ezutromid) in Boys With Duchenne Muscular Dystrop...To Assess the Activity and Safety of SMT...
-
Summit announces PhaseOut DMD did not meet primary endpointSummit Therapeutics announced today that...
-
Modified Diet Trial: A Study of SMT C1100 in Paediatric Patients With DMD Who Follow a Balanced DietPlacebo-controlled, multi-centre, random...
-
PhaseOut DMD: a Phase 2, proof of concept, clinical study of utrophin modulation with ezutromidThis study investigates the hypothesis t...
-
Utrophin modulators to treat Duchenne muscular dystrophy (DMD): Phase 1b Clinical Trial Results of SMT C1100Objective: To assess the safety, tolera...
-
Dame Kay Davies Explains Duchenne Muscular Dystrophy and Her Utrophin Researchhttps://player.vimeo.com/video/172905129...